Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 7/20 | 0.33 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962664 | 0.86 | P2RX1 (0.33) | LMNANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL29969013 | 0.74 | — | — | |
| SCHEMBL30660969 | 0.69 | — | — | |
| SCHEMBL21815682 | 0.68 | SIGMAR1 (0.38) | LMNANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL30292820 | 0.68 | SIGMAR1 (0.38) | LMNANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL9614870 | 0.67 | — | — | |
| SCHEMBL21066586 | 0.67 | KEAP1 (0.41) | LMNANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL1408252 | 0.67 | SIGMAR1 (0.36) | LMNANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL22028459 | 0.67 | SIGMAR1 (0.36) | LMNANPC1ALDH1A1TP53RAB9A | |
| SCHEMBL30919258 | 0.67 | SIGMAR1 (0.36) | LMNANPC1ALDH1A1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| EP-1792605-A1 | Use of at least a cationic cyanine derivative for use in hair dyeing, composition containg it process of treating keratinic fibres using the same composition, kit and use thereof | L'Oréal (FR) | 2007-06-06 | — | — | EP | claimed |
| EP-1509520-B1 | USE OF BENZO(C)QUINOLIZINIUM DERIVATIVES FOR THE TREATMENT OF DISEASES THAT ARE LINKED TO SMOOTH MUSCLE CELL CONSTRICTION | CENTRE NAT RECH SCIENT (FR) | 2006-11-22 | — | — | EP | claimed |
| US-6962925-B1 | Benzo(C)quinolizine derivatives and their use as 5α-reductases inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-08 | — | — | US | claimed |
| EP-1066284-B1 | BENZO(C)QUINOLIZINE DERIVATIVES AND THEIR USE AS 5 ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | EP | claimed |
| US-20050176747-A1 | Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-08-11 | — | — | US | claimed |
| US-6303622-B1 | FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2001-10-16 | — | — | US | claimed |
| EP-1066284-A1 | BENZO C]QUINOLIZINE DERIVATIVES AND THEIR USE AS 5 ALPHA-REDUCTASES INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2001-01-10 | — | — | EP | claimed |
| EP-0999747-A1 | USE OF BENZO C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2000-05-17 | — | — | EP | claimed |
| EP-0937044-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1999-08-25 | — | — | EP | claimed |
| WO-1999033828-A1 | BENZO[C]QUINOLIZINE DERIVATIVES AND THEIR USE AS 5 ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1999-07-08 | — | — | WO | claimed |
| EP-0926148-A1 | Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1999-06-30 | — | — | EP | claimed |
| WO-1999005913-A1 | USE OF BENZO[C]QUINOLIZINE DERIVATIVES AS PLANT GROWTH REGULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1999-02-11 | — | — | WO | claimed |
| EP-0880520-A1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1998-12-02 | — | — | EP | claimed |
| WO-1998005642-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-02-12 | — | — | WO | claimed |
| WO-1997029107-A1 | BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5α-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1997-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176747-A1 | Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction | MYLK, MYLK2, TNNI3 | LMNA 223/4885NPC1 4145/4885ALDH1A1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.